Reflucil

Quick links to important sections

Reflucil

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reflucil

What is Reflucil?

Reflucil is a pharmacological treatment developed for the management of gastroesophageal reflux disease (GERD) and associated acid-related disorders. It belongs to a class of medications known as proton pump inhibitors (PPIs), which are designed to reduce the production of gastric acid in the stomach.

Mechanism of Action

The active component in Reflucil targets the hydrogen-potassium adenosine triphosphatase enzyme system, commonly referred to as the proton pump, located within the parietal cells of the stomach lining. By inhibiting this specific enzyme system, the medication blocks the final stage of acid secretion. This results in a significant decrease in the acidity of the gastric juice, allowing the esophageal mucosa and stomach lining to recover from acid-induced irritation or erosions.

Therapeutic Intent

Reflucil is primarily utilized to provide relief from symptoms such as heartburn and acid regurgitation. Beyond symptom management, it is used in the treatment of various clinical conditions, including:

  • Erosive Esophagitis: Healing and maintenance of healed inflammation of the esophagus.
  • Gastric and Duodenal Ulcers: Supporting the recovery of sores in the lining of the stomach or the upper part of the small intestine.
  • Zollinger-Ellison Syndrome: Managing conditions characterized by pathological hypersecretion of gastric acid.

By maintaining a higher pH level in the stomach, Reflucil creates an environment conducive to the healing of damaged tissues and helps prevent further complications associated with chronic acid exposure.

What side effects are possible with Reflucil?

Reflucil’s safety profile, as documented in regulatory sources, outlines adverse reactions categorized by frequency and the physiological system affected. The majority of documented events are related to the gastrointestinal tract and transient laboratory value changes.

Frequency-Classified Adverse Reactions

The most commonly listed adverse reactions include diarrhea, loose stools, dry mouth, abdominal discomfort or pain, and headache. Regulatory documents also classify increases in hepatic enzymes (AST, ALT, gamma-GTP, Alkaline Phosphatase) as common events. Less common or rare effects include transient changes in blood counts, such as eosinophilia and leukopenia, as well as dizziness, insomnia, and palpitations.

Serious Adverse Reactions and Safety Constraints

Official labeling defines several serious adverse reactions. These include reports of Hepatitis and severe hepatic dysfunction, which in rare instances may be fatal. Additionally, specific cardiovascular risks, such as QT interval prolongation, have been documented.

Regulatory documents establish strict constraints on use. Reflucil is contraindicated in patients with known hypersensitivity to the drug and in individuals with conditions where increased gastric motility could be harmful, such as gastrointestinal hemorrhage, mechanical obstruction, or perforation. Furthermore, the label advises caution when administering the drug to older adults and those with existing hepatic or renal impairment, noting a potential for increased reaction tendency in these populations.

Exposure-Related Safety Note

Regulatory precautions advise against prolonged administration without adequate re-evaluation due to the documented potential for serious hepatic events. The overall safety structure emphasizes that while common effects are generally systemic or localized to the gut, the serious, clinically significant risks are primarily associated with the hepatobiliary and cardiovascular systems.

Overdose and Emergency Response

Overdose and When to Seek Help

Information regarding the clinical manifestations and management of Reflucil (Mosapride Citrate) overdose is based strictly on the officially documented guidance found in government regulatory sources.

Official Regulatory Stance on Overdose

The regulatory profile for Reflucil's overdose is defined by limited data. Official prescribing information confirms that data regarding overdosage with this medicine is limited.

Consequently, the official documents do not list specific clinical symptoms, signs, or laboratory abnormalities established to occur following an acute overdose event. Furthermore, specific supportive or procedural steps, such as gastric decontamination or a targeted antidote, are not formally described or required in the available regulatory labeling.


Immediate Actions Required

Due to the limited clinical data, the official regulatory guidance mandates a clear course of action:

Required Action Regulatory Status
Specific Overdose Symptoms Not formally documented
Antidote Availability Not formally documented
Help-Seeking Requirement Medical attention should be sought for any overdosage

If an overdose of Reflucil is suspected or confirmed, the regulatory documents explicitly require that medical attention must be sought immediately. This requirement is in place because the official label lacks specific, documented clinical guidance on managing the event.

Therapeutic Uses of Reflucil

What Reflucil Treats: Main Uses and Benefits

Reflucil is commonly used across therapeutic domains where short-term symptomatic assistance is needed for periods of heightened symptoms or distress. The medication is relevant in clinical contexts where supportive symptom management is appropriate for the patient's needs.

The medicine is used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. It is commonly used across conditions presenting with acute episodes and is relevant in situations involving recurrent or episodic manifestations.

Supporting Relief for Episodic Discomfort

Reflucil is used to manage acute clusters of symptoms that may arise suddenly or intensify over a short period. It is applied across domains where additional symptomatic support is needed, and may help with managing symptoms that interfere with daily comfort.

“It helps address groups of symptoms that may appear suddenly or intensify over time.”

Addressing Conditions with Fluctuating Symptoms

The medication is applicable in clinical settings marked by episodic or recurrent symptom patterns, particularly those characterized by periods of increased physiological stress or tension. Reflucil provides support that may assist patients with symptom fluctuations during these difficult, recurring manifestations.

Quick Fact: Supports managing symptoms that create noticeable interference.

Enhancing Day-to-Day Comfort and Stability

Reflucil is relevant in contexts marked by increased discomfort or tension. When symptoms become noticeable, it supports general well-being during symptomatic phases and contributes to easing the overall symptom load.

Eligibility and Restrictions for Use

Who Can and Cannot Use Reflucil? ️

Reflucil (Generic Name: [Insert Generic Name Here]) is a medication used to treat various conditions, and its use is generally determined by a healthcare provider. While it is safe for most people when prescribed appropriately, specific groups must avoid or use it with extreme caution.


Who Can Use Reflucil?

The medication is typically prescribed for adults and sometimes children (depending on the specific condition and formulation) who are diagnosed with conditions it is approved to treat. The decision rests on a comprehensive assessment of the patient's medical history and current health status.


Who Cannot Use Reflucil? (Contraindications)

Individuals with known hypersensitivity or allergic reactions to Reflucil or any of its inactive ingredients must not use this medication. Furthermore, its use is strictly contraindicated in patients with the following severe pre-existing conditions:

  • Severe Liver Impairment: Due to the drug's metabolism, significant liver disease may lead to dangerous accumulation.
  • Certain Cardiac Arrhythmias: Pre-existing heart rhythm disorders may be exacerbated by Reflucil.
Group Recommendation
Pregnant/Breastfeeding Consult a physician. Use only if the benefit justifies the potential risk to the fetus/infant.
Severe Kidney Disease Use with caution and often require a dosage adjustment by a healthcare provider.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Reflucil (Mosapride Citrate) has documented interaction patterns that require adherence to regulatory constraints regarding co-administration and timing. These interactions are classified based on their effect on drug exposure and pharmacodynamic outcomes.

Pharmacokinetic and Exposure Alteration

Co-administration with potent CYP3A4 Inhibitors, such as ketoconazole or erythromycin, is known to inhibit the enzyme responsible for Reflucil's metabolism. This documented pharmacokinetic interaction significantly increases the plasma concentration and systemic exposure of Reflucil. Additionally, Antacids may reduce Reflucil's absorption, leading to decreased systemic exposure. Patients with severe hepatic or kidney impairment may have heightened exposure-related interaction risks due to altered clearance.

Pharmacodynamic and Administration Restrictions

Official regulatory documents stipulate an absolute prohibition on co-administration with other medicinal products known to prolong the QT interval due to the additive risk of cardiac arrhythmias. Reflucil's prokinetic effect may be reduced (antagonized) by co-administration with Anticholinergic agents, requiring precautions such as spacing the doses to mitigate reduced efficacy. Concurrent use with other Serotonergic drugs increases the risk of additive serotonergic activity. Finally, alcohol may exacerbate certain CNS side effects, such as dizziness.

Mechanism of Action

Targeting the Rho/ROCK Pathway

Reflucil acts within the domain of enzyme-mediated signaling by inhibiting the Rho-associated protein kinase ( ROCK) enzymes, specifically ROCK1 and ROCK2. This molecular action modifies early steps in the Rho/ROCK cascade, which is critical for regulating the mechanical tension and shape of cells.


Modulating Trabecular Meshwork Contractility

The inhibition of ROCK initiates a cascade that leads to the relaxation of the actin cytoskeleton in the cells of the trabecular meshwork (TM), the eye’s primary drainage tissue. This biological process results in the decreased contractility of the TM tissue, which reduces its mechanical resistance to fluid flow.


Enhancing Conventional Aqueous Outflow

By relaxing the TM tissue and increasing its porosity, Reflucil directly improves the conventional aqueous humor outflow facility. This physiological adjustment results in a reduction in intraocular pressure (IOP), which is the systemic consequence of the mechanism’s action on the fluid dynamics.

Dosage and Administration Information

How to Use Reflucil: Official Administration Guidelines

Reflucil, containing the active ingredient Mosapride Citrate, is administered solely via the oral route. The medicine is available in several forms, including standard tablets in strengths of 2.5 mg and 5 mg. The usage patterns and dosing specifications follow established clinical guidelines.


Standard Adult Dosing and Frequency

For typical symptomatic use, the standard single adult dose is 5 mg of Mosapride Citrate, prescribed to be taken three times daily (TID), resulting in a total daily dose of 15 mg. Dosing is flexible concerning meals; the medicine can be taken either before or after meals.


Procedural and Time Constraints

Usage instructions establish a required time boundary for efficacy review: the regimen must be discontinued if no symptomatic improvement is observed after two weeks of treatment. If a scheduled dose is missed, it should be taken as soon as realized; however, the missed dose must be skipped if it is almost time for the subsequent dose to prevent taking two doses in close succession.


Population-Specific Use and Special Contexts

For older adults, administration requires careful monitoring. A dose reduction, such as an adjusted total daily dose of 7.5 mg, may be required based on clinical assessment. Furthermore, a specific, higher-dose regimen of 20 mg is used when the medicine serves as an adjunct during certain gastrointestinal lavage procedures. The use of this medicine in pediatric patients is not established due to a lack of clinical experience.

Recent Clinical Evidence

Reflucil: Recent Clinical Evidence

Reflucil has been studied primarily through Randomized Controlled Trials (RCTs) and meta-analyses across several gastrointestinal contexts. Research for Functional Dyspepsia (FD) mainly involved adult patients in Asian populations, examining outcomes like changes in overall symptom scores and the gastric emptying rate. Findings were often derived from short-term follow-up periods, typically two to twelve weeks. Similarly, studies exploring the drug's use for Gastroesophageal Reflux Disease (GERD) primarily evaluated it as an add-on treatment to standard anti-reflux medicine, assessing changes in reflux symptom scores. The physiological effect of the drug on gastric emptying itself was separately established in controlled clinical pharmacology studies involving healthy volunteers and small patient cohorts.

The evidence base also includes short-term RCTs that examined the drug's use in postoperative gastrointestinal recovery following major abdominal surgery. These trials monitored objective functional measures, such as the time to the first bowel movement, with observation periods limited to the first 5 to 10 days post-surgery. The results of these studies apply only to the specific cohorts examined.

Study Limitations and Evidence Gaps

Evidence is limited regarding long-term outcomes and the sustained nature of the observed patterns over periods exceeding three to six months. Study findings have been mixed when comparing results across different geographic populations for FD. Furthermore, data for certain groups remain insufficient, as the main clinical trials often excluded patients with severe comorbidities. For GERD, the findings were mixed regarding the added symptomatic effect when the drug was used alongside standard therapy, and the evidence base relies heavily on combination therapy studies.

Key Studies & References

  1. WHO ATC/DDD Index: Mosapride Citrate (A03FA09)
  2. Clinical Review of Mosapride for Gastroprokinetic Efficacy

Frequently Asked Questions (FAQ)

Common questions about Reflucil (FAQ)

Q: Do the side effects from Reflucil go away after the first week?

Official product information notes that common adverse effects, such as headache, diarrhea, or mild abdominal discomfort, are generally considered transient. This means the effects are expected to be short-lived and may eventually resolve, as is often the case with transient effects.

Q: How quickly should I start to notice Reflucil working?

Reflucil is classified as a prokinetic agent, meaning it starts working to increase the motility, or movement, of the digestive tract. This mechanism, which accelerates gastric emptying, begins shortly after administration.

Q: Where can I find the clinical trial results for Reflucil?

The key summaries of the non-clinical and clinical trial data are made publicly available by regulatory authorities. These summaries can typically be found within the Public Assessment Reports or review documents published by agencies such as the FDA or the EMA.

Q: Does taking Reflucil affect the body's metabolism?

According to pharmacokinetic studies, the medicine is processed, or metabolized, in the body primarily by the liver. Specifically, it uses the Cytochrome P450 3A4 enzyme, a common pathway for drug processing.

Q: Why do some people experience mild headaches when starting Reflucil?

Headache is a commonly reported adverse effect noted during the clinical trials for Reflucil. While official prescribing information confirms it as a known side effect, it does not detail the specific physiological reason or cause for its occurrence.

Q: Is Reflucil a generic or a brand-name medication?

Reflucil is a brand name for the active ingredient, Mosapride Citrate. The active substance itself is available to patients under various brand names, as well as in generic medicine formulations.

Q: Is Reflucil meant to fully cure the condition or only manage its symptoms?

Studies and official information indicate that this medication is primarily used for the treatment of gastrointestinal symptoms. Its main purpose is to manage discomfort and other issues associated with conditions like chronic gastritis.

Q: Can I crush or chew Reflucil tablets if I have trouble swallowing pills?

Regulatory guidance indicates that the tablets are to be swallowed whole. The medicine is not intended to be crushed, broken, or chewed before swallowing.

Q: Is Reflucil a medication that requires regular blood tests?

Because of the documented potential for serious hepatic events, official guidelines recommend close monitoring of liver function. This may include regular blood tests, particularly if the treatment regimen is prolonged.

Q: What research was done to determine who cannot use Reflucil?

The determination of who cannot use the medication is based on a rigorous regulatory process. This includes findings from non-clinical studies, such as toxicology, and clinical trial data, which identify risks like hypersensitivity.

Q: Does Reflucil have any listed common interactions with food products?

The official product information suggests avoiding the use of grapefruit juice concurrently with the medication. This is because it may increase the levels of the medicine in the body, potentially leading to increased exposure.

Q: Can Reflucil be taken if a person has high blood pressure?

Caution is generally advised for patients who have underlying cardiac disorders or heart conditions. The official prescribing information notes a minimal risk of affecting the QTc interval, which is a measure of heart rhythm.

Q: Can I take Reflucil if I have a history of anxiety or depression?

Regulatory documents advise caution when using this medication alongside other medicines that act as central nervous system (CNS) depressants. This is due to the potential for additive effects in the body.

Q: Are there any known allergens in the ingredients of Reflucil?

The prescribing information notes that the medicine is contraindicated for individuals with a known hypersensitivity or allergy to the active substance or any of the inactive ingredients, also known as excipients. The full list of excipients is available within the official prescribing information.

Q: How long does Reflucil stay in the body after the last dose is taken?

Pharmacokinetic studies indicate that the elimination half-life of the active substance is quite short, typically ranging from about 1.6 to 2.4 hours. The half-life refers to the time it takes for the concentration of the medicine in the body to reduce by half.

Q: Does Reflucil carry any risk of dependency or withdrawal symptoms?

According to official regulatory categorization, Reflucil is not designated as a controlled substance. It is not listed as a habit-forming drug that carries a risk of dependency.

Q: What should I do if I experience a very rare but severe side effect from Reflucil?

Official patient information states that if you experience serious symptoms, such as feeling generally unwell (malaise), loss of appetite, or yellowing of the skin (jaundice), the medication should be discontinued and medical attention should be immediately sought.

Q: How long does the main effect of one dose of Reflucil last?

The product's posology indicates administration three times daily, which aligns with its short elimination half-life in the body. This regimen is designed to maintain the therapeutic effect needed to support digestive tract motility throughout the day.

Q: Can Reflucil be used by people with specific dietary restrictions (e.g., vegan)?

The official prescribing information includes a complete list of all inactive ingredients, or excipients, used in the formulation of the product. Patients with specific dietary restrictions are advised to consult this list to verify the medication's suitability.

How should Reflucil be stored and disposed of?

How to Store and Dispose of Reflucil?

The stability and safety of Reflucil (Mosapride Citrate) are governed by specific storage and disposal rules documented in official regulatory labeling.

Official Storage Requirements

  • Temperature and Environment: Store the medicine at temperatures not exceeding 30 C and keep it strictly protected from light and moisture. Direct sunlight and high humidity must be avoided.
  • Packaging: Always keep Reflucil in the original, tightly closed container to preserve product integrity. Do not use the medicine after the official expiry date (EXP).
  • Child Safety: It is mandatory to store this prescription medicine out of the sight and reach of children at all times.

Official Disposal Instructions

  • Pharmaceutical Waste: Unused or expired Reflucil must not be disposed of via household waste or wastewater (flushed down the toilet or sink).
  • Collection: Unused medicine should be returned to a pharmacist or a local official collection program for disposal in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reflucil found in:

A-Z Index: